रुबिकॉन रिसर्च शेअर किंमत

वृत्तपत्र प्रकाशन

• बीएसई इंडिया
• 1 दिवस 10 तासांपूर्वी

Audio Recording of earnings conference call for the quarter ended 30th June, 2026

• बीएसई इंडिया
• 2 दिवसांपूर्वी

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Rubicon Research announced Q1FY27 results</strong></span></h3><p _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">एकत्रित फायनान्शियल हायलाईट्स: </strong></p><ul><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Revenue from Operations:</strong> The company reported revenue of Rs 5,343.38 million in Q1FY27, representing a YoY growth of 51.59% compared to Rs 3,524.94 million in Q1FY26 and a QoQ growth of 3.97% from Rs 5,139.15 million in Q4FY26.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Total Income:</strong> Total income for Q1FY27 stood at Rs 5,400.21 million, increasing by 52.92% YoY from Rs 3,531.27 million and by 4.55% QoQ from Rs 5,165.25 million.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Net Profit after Tax:</strong> The company achieved a Net Profit of Rs 847.81 million in Q1FY27, a significant increase of 95.79% YoY from Rs 433.01 million. On a QoQ basis, profit grew by 10.41% from Rs 767.85 million in Q4FY26.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Total Comprehensive Income:</strong> Total comprehensive income for the quarter was Rs 800.49 million in Q1FY27 compared to Rs 504.18 million in Q1FY26 and Rs 827.39 million in Q4FY26.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Earnings Per Share (EPS):</strong> Basic EPS grew to Rs 5.13 in Q1FY27 from Rs 2.81 in Q1FY26. Diluted EPS stood at Rs 5.08 compared to Rs 2.79 in the same period last year.</li></ul><p><strong _ngcontent-ng-c3466788764="">स्टँडअलोन फायनान्शियल हायलाईट्स: </strong></p><ul><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Revenue from Operations:</strong> Standalone revenue was Rs 4,277.30 million in Q1FY27, up 53.85% YoY from Rs 2,780.26 million and up 9.71% QoQ from Rs 3,898.78 million in Q4FY26.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Total Income:</strong> Total standalone income reached Rs 4,301.41 million in Q1FY27, showing a growth of 53.92% YoY compared to Rs 2,794.64 million and 9.32% QoQ growth from Rs 3,934.59 million.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Net Profit after Tax:</strong> Net profit for the standalone entity stood at Rs 824.49 million in Q1FY27, an increase of 134.55% YoY from Rs 351.52 million. QoQ profit increased by 17.75% from Rs 700.20 million in Q4FY26.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Total Comprehensive Income:</strong> Standalone total comprehensive income was Rs 825.01 million in Q1FY27 compared to Rs 347.93 million in Q1FY26.</li></ul><p><strong _ngcontent-ng-c3466788764="">बिझनेस हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Segment Performance:</strong> The company is primarily engaged in a single business segment, namely the "Sale of Pharmaceutical products."</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Strategic Acquisition:</strong> During the quarter, the company completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026, for a total consideration of Rs 1,759.17 million.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">International Expansion:</strong> AdvaGen Holdings’ Inc., a wholly-owned subsidiary, acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC for an enterprise value of USD 2.9 million.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">Proposed Amalgamation:</strong> The Board approved a Scheme of Amalgamation on July 20, 2026, to merge Kia Health Tech Private Limited with Rubicon Research Limited.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">IPO Fund Utilization:</strong> Out of the net IPO proceeds of Rs 4,712.74 million received in the previous year, the company has utilized Rs 3,907.05 million up to June 30, 2026. The timeline for the utilization of unutilized proceeds has been extended to March 31, 2027.</li><li _ngcontent-ng-c3466788764=""><strong _ngcontent-ng-c3466788764="">R&D Investment:</strong> The company incurred research and development revenue expenditure of Rs 600.69 million on a consolidated basis during Q1FY27.</li></ul><p><a class="lb" href="/marathi/get-document/post/pdf/5792849/" target="_blank">रिझल्ट PDF</a></p>

• ट्रेंडलाईन
• 2 दिवस 5 तासांपूर्वी